| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia SE Maynard, JY Min, J Merchan, KH Lim, J Li, S Mondal, TA Libermann, ... The Journal of clinical investigation 111 (5), 649-658, 2003 | 5238 | 2003 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2213 | 2013 |
| Sunitinib in patients with metastatic renal cell carcinoma RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ... Jama 295 (21), 2516-2524, 2006 | 1645 | 2006 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1529 | 2021 |
| Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial BA Wilky, MM Trucco, TK Subhawong, V Florou, W Park, D Kwon, ... The lancet oncology 20 (6), 837-848, 2019 | 348 | 2019 |
| A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma PJ Hosein, J Macintyre, C Kawamura, JC Maldonado, V Ernani, ... BMC cancer 12, 1-7, 2012 | 268 | 2012 |
| A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials BC Leibovich, JC Cheville, CM Lohse, H Zincke, I Frank, ED Kwon, ... The Journal of urology 174 (5), 1759-1763, 2005 | 251 | 2005 |
| Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis TK Choueiri, TM Bauer, KP Papadopoulos, ER Plimack, JR Merchan, ... Nature medicine 27 (5), 802-805, 2021 | 232 | 2021 |
| Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, ... Journal of clinical oncology 41 (1), 22-31, 2023 | 201 | 2023 |
| A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer PJ Hosein, G de Lima Lopes Jr, VH Pastorini, C Gomez, J Macintyre, ... American journal of clinical oncology 36 (2), 151-156, 2013 | 142 | 2013 |
| Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. JE Rosenberg, TW Flaig, TW Friedlander, MI Milowsky, S Srinivas, ... Journal of Clinical Oncology 38 (6_suppl), 441-441, 2020 | 128 | 2020 |
| Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma G Narayanan, PJ Hosein, IC Beulaygue, T Froud, HJ Scheffer, SR Venkat, ... Journal of Vascular and Interventional Radiology 28 (3), 342-348, 2017 | 125 | 2017 |
| Antiangiogenic activity of 2-deoxy-D-glucose JR Merchan, K Kovács, JW Railsback, M Kurtoglu, Y Jing, Y Piña, N Gao, ... PloS one 5 (10), e13699, 2010 | 124 | 2010 |
| EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video) G Ascunce, A Ribeiro, I Reis, C Rocha-Lima, D Sleeman, J Merchan, ... Gastrointestinal endoscopy 73 (2), 267-274, 2011 | 119 | 2011 |
| Renal cancer: molecular mechanisms and newer therapeutic options SA Karumanchi, J Merchan, VP Sukhatme Current opinion in nephrology and hypertension 11 (1), 37-42, 2002 | 119 | 2002 |
| Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial R Motzer, TE Hutson, J Reeves, R Hawkins, J Guo, P Nathan, M Staehler, ... Annals of Oncology 23, ixe13, 2012 | 118 | 2012 |
| A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma SN Markovic, VJ Suman, RA Rao, JN Ingle, JS Kaur, LA Erickson, ... American journal of clinical oncology 30 (3), 303-309, 2007 | 118 | 2007 |
| Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox‐2 inhibition JR Merchan, DR Jayaram, JG Supko, X He, GJ Bubley, VP Sukhatme International journal of cancer 113 (3), 490-498, 2005 | 106 | 2005 |
| Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised … TK Choueiri, M Eto, R Motzer, U De Giorgi, T Buchler, NS Basappa, ... The Lancet Oncology 24 (3), 228-238, 2023 | 105 | 2023 |
| Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results JR Merchan, G Liu, T Fitch, J Picus, R Qin, HC Pitot, W Maples, ... Journal of Clinical Oncology 25 (18_suppl), 5034-5034, 2007 | 99 | 2007 |
